CureVac N.V. Forecast, price target & analysts
CureVac N.V. Target price 2025 - Analyst rating & recommendation
CureVac N.V. Classifications & Recommendation:
CureVac N.V. Price Target
| Target Price | $5.57 |
| Price | $5.36 |
| Potential |
3.90%
register free of charge
|
| Number of Estimates | 8 |
|
8 Analysts have issued a price target CureVac N.V. 2026 .
The average CureVac N.V. target price is $5.57.
This is
3.90%
register free of charge
$5.78
7.74%
register free of charge
$2.02
62.31%
register free of charge
|
|
| A rating was issued by 13 analysts: 6 Analysts recommend CureVac N.V. to buy, 7 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the CureVac N.V. stock has an average upside potential 2026 of
3.90%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2032
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 632.40 | 83.25 |
| 895.59% | 86.84% | |
| EBITDA Margin | 36.83% | -144.25% |
| 107.97% | 491.69% | |
| Net Margin | 30.31% | -153.68% |
| 106.26% | 607.11% |
9 Analysts have issued a sales forecast CureVac N.V. 2025 . The average CureVac N.V. sales estimate is
This results in the following potential growth metrics:
6 Analysts have issued an CureVac N.V. EBITDA forecast 2025. The average CureVac N.V. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
9 CureVac N.V. Analysts have issued a net profit forecast 2025. The average CureVac N.V. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2032
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | 0.85 | -0.57 |
| 161.15% | 167.06% | |
| P/E | negative | |
| EV/Sales | 9.39 |
9 Analysts have issued a CureVac N.V. forecast for earnings per share. The average CureVac N.V. EPS is
This results in the following potential growth metrics and future valuations:
Current CureVac N.V. Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| UBS |
Locked
➜
Locked
|
Locked | Jun 26 2025 |
| Jefferies |
Locked
➜
Locked
|
Locked | Jun 13 2025 |
| JMP Securities |
Locked
➜
Locked
|
Locked | May 28 2025 |
| UBS |
Locked
➜
Locked
|
Locked | Apr 30 2025 |
| JMP Securities |
Locked
➜
Locked
|
Locked | Feb 14 2025 |
| JMP Securities |
Locked
➜
Locked
|
Locked | Sep 16 2024 |
| Analyst Rating | Date |
|---|---|
|
Locked
UBS:
Locked
➜
Locked
|
Jun 26 2025 |
|
Locked
Jefferies:
Locked
➜
Locked
|
Jun 13 2025 |
|
Locked
JMP Securities:
Locked
➜
Locked
|
May 28 2025 |
|
Locked
UBS:
Locked
➜
Locked
|
Apr 30 2025 |
|
Locked
JMP Securities:
Locked
➜
Locked
|
Feb 14 2025 |
|
Locked
JMP Securities:
Locked
➜
Locked
|
Sep 16 2024 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
